Protagonist Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Protagonist Therapeutics, Inc. (PTGX) on April 4, 2023, reporting events occurring on that date. The company is a Delaware corporation with principal executive offices in Newark, California, and its common stock trades on The Nasdaq Stock Market, LLC.
Key Financial Metrics
This filing does not report historical revenue, profit, cash flow, margins, or debt levels. The primary financial event disclosed is a public equity offering:
- Shares Offered: 5,000,000 shares of common stock.
- Public Offering Price: $20.00 per share.
- Price to Company: $18.80 per share (net of underwriting discounts).
- Expected Gross Proceeds: Approximately $100.0 million (before deducting underwriting discounts, commissions, and offering expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 750,000 shares.
Material Changes
The material change reported is the execution of an Underwriting Agreement with J.P. Morgan Securities LLC, Jefferies LLC, and Piper Sandler & Co. This transaction represents a significant capital raise intended to fund the company's operations and development programs. The offering is expected to close on April 10, 2023, subject to customary closing conditions.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future performance, or specific risk factors beyond standard underwriting agreement terms. The transaction is subject to customary closing conditions and representations, warranties, and indemnification obligations typical for such agreements. The offering was conducted pursuant to a shelf registration statement effective August 16, 2022.
Investor Verification Checklist
- Verify the final closing date of the offering (expected April 10, 2023) and whether the over-allotment option was exercised.
- Review the final prospectus supplement filed on April 5, 2023, for detailed use of proceeds and specific offering expenses.
- Confirm the net proceeds received after deducting underwriting discounts and commissions.
- Check subsequent filings for any dilution impact on existing shareholders.